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Background: Emergency abdominal surgery carries a 15% to 20% short-term mortality rate. Postoperative medical
complications are strongly associated with increased mortality. Recent research suggests that timely recognition
and effective management of complications may reduce mortality. The aim of the present trial is to evaluate the
effect of postoperative intermediate care following emergency major abdominal surgery in high-risk patients.
Methods and design: The InCare trial is a randomised, parallel-group, non-blinded clinical trial with 1:1 allocation.
Patients undergoing emergency laparotomy or laparoscopic surgery with a perioperative Acute Physiology and
Chronic Health Evaluation II score of 10 or above, who are ready to be transferred to the surgical ward within 24 h
of surgery are allocated to either intermediate care for 48 h, or surgical ward care. The primary outcome measure is
all-cause 30-day mortality. We aim to enrol 400 patients in seven Danish hospitals. The sample size allows us to
detect or refute a 34% relative risk reduction of mortality with 80% power.
Discussion: This trial evaluates the benefits and possible harm of intermediate care. The results may potentially
influence the survival of many high-risk surgical patients. As a pioneer trial in the area, it will provide important data
on the feasibility of future large-scale randomised clinical trials evaluating different levels of postoperative care.
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Worldwide an estimated 234 million surgical procedures
are performed every year [1]. Overall, non-cardiac sur-
gery carries low postoperative mortality rates of 1.4% to
1.9% [2-4]. However, this conceals the fact that a sub-
group has a high risk of postoperative death. This high-
risk group comprises patients often of advanced age with
significant co-existent disease undergoing complex
emergency surgery [4]. Emergency abdominal surgery
carries a 15% to 20% short-term mortality rate [5-8],
with cardiopulmonary complications and sepsis as the
most frequent causes of death [9]. Postoperative medical
complications are more important determinants of post-
operative death than preoperative demographic charac-
teristics, and intraoperative adverse events [8,10]. Recent
research suggests that timely recognition, and effective
management, of postoperative complications may reduce
mortality [11]. Thus, early routine postoperative admis-
sion of high-risk non-cardiac surgical patients to inten-
sive or intermediate care units could prove important.
However, many countries have limited access to these fa-
cilities [4,12]. The majority of high-risk non-cardiac sur-
gical patients are consequently treated on standard
surgical wards with restricted resources for monitoring,
and advanced treatment methods [4,13]. Intermediate
care (IC) could be an appropriate level of care for stable
postoperative patients with an a priori high risk of com-
plications and death. IC is generally defined as a level of
care intermediate between that provided by a general
ward and an intensive care unit. An IC unit monitors
and supports patients with, or likely to develop, acute
(or acute on chronic) single organ failure [14-16]. The
effect of postoperative IC compared to ward care on
high-risk surgical patients’ outcome is only sparsely eval-
uated, and never in a randomised clinical trial [17-23]
(Additional file 1: Search string).
The aim of the InCare trial is to evaluate the effect of
postoperative IC following emergency major abdominal
surgery in high-risk patients identified by an Acute Phy-
siology and Chronic Health Evaluation (APACHE) II score
of 10 or above. The APACHE II score is a well-established
classification system of the severity of diseases used in
intensive care units worldwide [24], which can be used on
emergency major abdominal surgical patients as well
[5,25-31]. Emergency major abdominal surgical patients
with an APACHE II score of 10 to 11 and above have a
28% to 45% mortality rate compared to patients with an
APACHE II score below 9 and 10 who evidence a mortal-
ity rate of 0% to 7% [27-31]. We hypothesise that post-
operative IC will lead to a reduction in postoperative
mortality by avoidance of, or timely recognition and effect-
ive management of, postoperative complications. Further-
more, we hypothesise that early admission to postoperative
IC may reduce later admission to intensive care.Methods and design
Trial design
The InCare trial is an ongoing multicentre, randomised,
parallel-group, non-blinded clinical trial with 1:1 allocation.
Emergency abdominal surgical patients are postoperatively
allocated to either: (1) IC for 48 h; or (2) surgical ward care
(standard treatment). The trial was initiated in October
2010, and we aim to enrol 400 patients.
Setting
In Denmark all emergency surgical patients are treated
in tax-financed public-healthcare centres. The total in-
tensive and intermediate care availability in Denmark is
8.3 beds per 100,000 citizens in 2010, with seven inten-
sive care beds per 100,000 citizens and 1.3 intermediate
care beds per 100,000 citizens (unpublished data from
The Danish Regions central office). In comparison the
intensive care availability in the United States was 20.0
per 100,000 citizens, and in the United Kingdom it was
3.5 per 100,000 citizens in 2005 [32]. Currently seven
Danish tertiary referral university affiliated public-
healthcare centres are participating in the trial.
Inclusion criteria
Patients are eligible for inclusion if: (1) they have under-
gone emergency gastrointestinal laparotomy or laparo-
scopic surgery; (2) they are ready to be transferred to the
ward after a postoperative stay in a post-anaesthesia care
unit or an intermediate/intensive care unit for <24 h;
and (3) they have a perioperative APACHE II score of
≥10. We define emergency surgery as indicated surgery,
which should be undertaken within 24 h.
Because of slower enrolment rate than anticipated, the
steering committee have decided to include patients with
Apache II scores of 10 and 11 although the original in-
clusion criteria was an Apache II score ≥12. This was
initiated on 23 May 2012 after 192 enrolled patients.
Patients with Apache II scores of 10 and 11 also have a
high 30-day mortality and the potential to benefit from
the IC intervention [27-31].
Exclusion criteria
Exclusion criteria are as follows: (1) appendectomy; (2)
laparoscopic cholecystectomy; (3) negative diagnostic
laparoscopy; (4) intensive care not indicated (patients on
palliative care, or with irreversible organ failure); (5) pre-
vious participation in the trial; (6) age <18 years; (7)
trauma; and (8) no IC bed available.
Recruitment, screening and enrolment
We recruit patients postoperatively in the post-anaesthesia
care unit and intensive/intermediate care unit. All adult
patients who have undergone the relevant surgical proce-
dures have a venous and arterial blood gas sample taken
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site standard postoperative vital-sign monitoring is
ensured, enabling calculation of the APACHE II score,
when patients are ready to be transferred to the sur-
gical ward in accordance with the trial site’s discharge
criteria - local adjusted versions of the Danish national
recommendations [33] (Additional file 2: National dis-
charge recommendations). At this point of time the
attending anaesthetist screens for trial eligibility using a
standard screening form with flowcharts (Figure 1). If
none of the exclusion criteria 1 to 7 apply, the APACHE II
score is calculated from the worst parameter values mea-
sured 12 h preoperatively, peroperatively, and up to 12 h
postoperatively. If there is missing data for the APACHE
II score calculation, when the patient is transferable to the
ward, current values are used. GCS score, blood pressure
and heart rate recorded during anaesthesia are not
included in the APACHE II score calculation. The APA-
CHE II score is calculated electronically on the InCare
trial website [34]. If the patient has an APACHE II score
of ≥10 the anaesthetist checks that an IC bed can be estab-
lished at the intermediate care, intensive care or post-
anaesthesia care unit. If an IC bed is not available, the
patient is registered as ‘not included due to lack of IC bed’
and transferred to the ward. If an IC bed is available,
written consent is obtained from the patient or a legal rep-
resentative, if the patient is incapable. If it is not possible
to contact a legal representative within 2 h, the patient is
included in the trial, and written consent is obtained as
soon as possible.
Randomisation
The patients are randomised using a telephone-based
central interactive-voice-response system managed byYes
 10
Yes
No
No
9
Emergency laparotomy or 
No exclusion criteria 1-7
APACHE II scoring 
Enrol
Consent?
Is there an available IC bed?
Ready to be transfer
Figure 1 Screening flowchart.the Copenhagen Trial Unit (CTU). The randomisation
system is accessible around the clock. It ensures imme-
diate computer-based allocation, and adequate allocation
concealment. A computer-generated block randomisa-
tion, with the investigators unknown and varying block
size is used. Stratification variables are: trial site; APA-
CHE II score (10 to 14 or ≥15); and perforated viscera
(yes versus no).
Interventions
Intermediate care
IC is initiated as soon as the patient is allocated, and
continues for at least 48 h. The IC bed is situated at an
intermediate care, an intensive care or a post-
anaesthesia care unit, which can provide the outlined
intervention (Table 1). IC is defined as a minimal moni-
toring level and maximal treatment level. The minimal
monitoring level is applied when the patient’s vital signs
are stable. If the patient deteriorates, the level of moni-
toring and treatment is increased as indicated. When the
maximal level of treatment defined in the IC is exceeded,
that is when there is a need for invasive ventilation,
emergency dialysis, parallel sympathomimetic drug infu-
sion or invasive arterial-blood pressure monitoring, the
patient is categorised as an intensive care patient. How-
ever, the patient remains in the trial for observation of
the outcome measures. Surgeons and intensivists make
compulsory protocol-based rounds on a daily basis using
a standard form (Additional file 3: Surgeon - protocol-
based round and Additional file 4: Intensivist - protocol-
based round). All medical treatment and investigations
are made on medical indication alone, not determined
by the trial-protocol. Forty-eight hours after randomisa-
tion, or at morning handover if the patient is included atlaparoscopy and
Fulfil exclusion criteria 1-7 
Registered on the screening 
list as:
- Fulfilling exclusion criteria 1-7
- APACHE II score 9 or below 
- Not included due to lack of IC
bed
- No consent
red to ward
Table 1 Definition of intermediate care
Observation Minimal monitoring levela Treatments goalsb Comments
Level of consciousness Every 8 h GCS: 15
Respiratory rate Every second hour RR: 10 to 20 If the patient has stable vital signs the
RR is not measured during nights
Oxygenation Continuous pulse oximetry SpO2 ≥94% Continuous pulse oximetry when the
patient is supine or sitting in a chair.
Discontinued during mobilisation
Blood pressure Every second hour MAP: 65 to 110 mmHg If the patient has stable vital signs the
MAP is not measured during nights
Heart rate Continuous ECG monitoring HR: 50 to 100 Continuous ECG when the patient is
supine or sitting in chair. Discontinued
during mobilisation. Diagnostic ECG on
indication. If arrhythmia or ischaemia is
detected the treatment goals are adjusted
to current recommendations
No ischemia
Diuresis Every hour ≥0.5 mL/kg/h During mobilisation the diuresis is
summed every third hour
Temperature Every 8 h 36°C to 38°C
Pain Visual Assessment Score Every 8 h VAS: 0 to 2 during rest No VAS scoring during sleep
Epidural: Able to move both legs
Central venous pressure Every 8 h 8 to 12 mmHg CVP and S cVO2 is only registered if there
is a central venous catheter in place. The
central venous catheter is removed when
possible
Central venous oxygen saturation Every 8 h SpO2 ≥ 70%
Standard blood samples Every 24 h Within normal reference values Hgb ≥4.5 mmol/L
Hgb ≥6.0 during sepsis or heart disease
Treatment (if needed) Maximal treatment level Treatments goals Comments
Single sympathomimetic drug support Continuously MAP: ≥65 mmHg
Diuresis: ≥0.5 mL/kg/h
Oxygen therapy on open systems Continuously SpO2 ≥94% Unless contraindicated, oxygen therapy is
discontinued when oxygenation is ≥94%
without oxygen therapy. During nights:
minimum 2 L supplemental oxygen is
given
Positive Expiratory Pressure (PEP) therapy Assistance to PEP therapy:
once per hour
SpO2 ≥94% If the patient does not need assistance
with PEP therapy, guidance in self-
administration of PEP therapy must be
available
Non-invasive ventilation Continuously Normocapnia and normoxic
Volume / Fluid therapy Continuously MAP: ≥65 mmHg Fluid balance: Evaluation frequency in
accordance with monitoring level and
vital signs
Diuresis: ≥0.5 mL/kg/h
S cVO2 ≥70%
CVP: 8 to 12 mmHg
During evening and night shifts: Staff specialist in anaesthetist/intensive care medicine on in-house duty and staff specialist in surgery on call.
aThe minimal monitoring level is exceeded when necessary (for example, deterioration).
bAll treatment goals are adjusted to the individual patient’s co-morbidities, physiological status and in the event of complications in agreement with current
recommendations (for example, troponin T/I is measured when cardiac ischaemia is suspected).
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local discharge criteria are met, they can be transferred
to the surgical ward.
Ward care
Patients allocated to ward care (WC) are transferred to the
surgical ward with a protocol-based discharge note using astandard form (Additional file 5: Anaesthetist - discharge
note). Patients are thoroughly evaluated before transfer,
and a written plan of treatment and monitoring for the
first 24 h in the ward is outlined in the medical chart.
Otherwise, surgical ward treatment is as standard for the
individual ward. In general, the participating surgical
wards have the resources and facilities to meet the
Table 2 Surgical ward care: an overview of facilities
Observation Monitoring level Treatments goalsa Comments
Level of consciousness Every 8 h GCS: 15
Respiratory rate Every 8 h RR: 10 to 20
Oxygenation Every 8 h SpO2 ≥94% Continuous pulse oximetry is not available
Blood pressure Every 8 h MAP: 65 to 110 mmHg
Heart rate Every 8 h HR: 50 to 100 Continuous ECG is not available. Diagnostic
ECG on indication. If arrhythmia or ischaemia
is detected the treatment goals are adjusted
to current recommendations
No ischaemia
Diuresis Every 8 h ≥0.5 mL/kg/h
Temperature Every 8 h 36°C to 38°C
Pain Visual Assessment Score Every 8 h VAS: 0 to 2 during rest Epidural:
Able to move both legs
Central venous pressure Not available
Central venous oxygen saturation Not available
Standard blood samples Every 24 h Within normal reference values Hgb ≥4.5 mmol/L
Hgb ≥6.0 during sepsis or heart disease
Treatment (if needed) Maximal treatment level Treatments goals Comments
Infusion of sympathomimetic drugs Not available
Oxygen therapy on open air systems Continuously SpO2 ≥94% Unless contraindicated. Oxygen therapy is
discontinued when oxygenation is above
≥94% without oxygen therapy. During
nights: minimum 2 L supplemental oxygen
is given
Positive Expiratory Pressure (PEP) therapy Assistance to PEP therapy:
every fourth hour during
day and evening shift
SpO2 ≥94% If the patient does not need assistance with
PEP therapy, guidance in self-administration
of PEP therapy is available
Non-invasive ventilation Not available
Volume / Fluid therapy Continuously Systolic blood pressure:
≥100 mmHg
Fluid balance: Evaluation frequency in
accordance with monitoring level and vital
signsDiuresis: ≥12 mL/kg/day
During evening and night shifts: Resident in surgery on in-house duty and staff specialist in surgery on call. Staff specialist in anaesthesiology/intensive care
medicine on call from in-house duty.
aAll treatment goals are adjusted to the individual patient’s co-morbidities, physiological status and in the event of complications in agreement with
current recommendations.
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level can only be exceeded for a short time, and it is not
possible to initiate continuous monitoring of vital signs. If
patients deteriorate they are transferred to an intermediate
care, or intensive care unit to be treated appropriately.
Baseline data
After inclusion we register the following demographic
characteristics: dementia; previous stroke; chronic ob-
structive pulmonary disease; previous pulmonary embol-
ism; previous myocardial infarction; chronic kidney
dialysis; cancer; tobacco habit; alcohol consumption; assist-
ance with personal hygiene; The American Society of
Anaesthesiologists’ Physical Status Classification (ASA)
score, and the postoperative sepsis score: grade 0, no sepsis
and no systemic-inflammatory-response-syndrome (SIRS);
grade 1, SIRS; grade 2, sepsis; grade 3, severe sepsis; and
grade 4, septic shock [35]. We collect the following peri-
operative data: nature and duration of surgery; method ofanaesthesia; location and duration of post-anaesthesia care;
infusion of sympathomimetic drug (yes/no); blood loss;
volume of crystalloid and/or colloid infusion; and infusion
of blood products (type and number of units).
Intervention period data
We measure compliance with the trial protocol by regis-
tering the frequency of observations of the measures
listed in Table 3, made during the 48 h intervention
period. Additionally, we register the following measures
regarding level of treatment and monitoring in both
groups: early-warning-score system [36] monitoring for
>24 h (yes/no); nutrition initiated within 24 h (yes/no);
mobilisation within 24 h of surgery (yes/no; level);
mobilisation within 48 h of surgery (yes/no; level);
intensivist or anaesthetist evaluation (number; specialist/
non-specialist), and surgeon evaluation (number; spe-
cialist/non-specialist). Additionally, we register the use
of diagnostic imaging: chest X-ray; lung scintigraphy; and
Table 3 Compliance with trial protocol
Measures IC Group (day 2)a WC Group (day 14)a
Actual monitoring level
Level of consciousness (number of registrations) x x
Respiratory rate (number of registrations) x x
Continuous pulse oximetry (yes/no) x x
Blood pressure (number of registrations) x x
Continuous ECG monitoring (yes/no) x x
24-h diuresis (number of registrations) x x
Hourly diuresis registration for >24 h (yes/no) x x
Temperature (number of registrations) x x
Pain Visual Assessment Score (no. of registrations) x x
Central venous pressure (number of registrations) x x
Central venous oxygen saturation (number of samples) x x
Standard blood samples (number of samples) x x
Treatment level
Infusion of sympathomimetic drugs (yes/no) x x
Parallel infusion of sympathomimetic drugs (yes/no) x x
>2 L supplemental oxygen during nights (yes/no) x x
Assistance to PEP therapy (number of treatments) x x
Non-invasive ventilation (yes/no) x x
Invasive ventilation (yes/no) x x
Emergency dialysis (yes/no) x x
24-h fluid balance calculation (number of registrations) x x
Protocol-based discharge by anaesthetist (yes/no)b x
Protocol-based round by intensivist (number) x
Protocol-based round by surgeon (number) x
Patient location (hours)c x x
Data stem from medical charts, nurse charts and observation charts used in the 48-h intervention period.
aTiming of registration of compliance to protocol in the case report form.
bRegistered by the anaesthetist writing the discharge note and checked at day 14.
cPost-anaesthesia care unit; intermediate care bed; intensive care bed; surgical ward; medical ward; and/or coronary care unit.
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premature or late transfer to the surgical ward (respectively
before or after 48 h intervention); ‘step-up’ to an intensive
care bed; the Simplified Acute Physiology Score (SAPS) II
[37]; the Sequential Organ Failure Assessment (SOFA)
score (day 1 and 2) [38]; and the sepsis score (day 2).
Follow-up
Mortality data will be retrieved from The Danish Civil
Registration System (CRS) [39]. The CRS contains mor-
tality data on all Danish citizens, through a unique
personal identification number. The retrieval from CRS
will be made by an independent data manager at Copen-
hagen Trial Unit at interim analysis and at day 30 after
the last patient has been enrolled. The secondary out-
come measures are registered from the medical chart at
day 30 postoperatively, and from the National Patient
Registry (NPR), which contains data on hospitalisation
of all Danish citizens [40]. Furthermore, return tooperating theatre, and postoperative medical and surgi-
cal complications requiring treatment within 14 days of
randomisation, are retrieved from the medical chart at
day 30.
Outcome measures
The primary outcome measure is all-cause 30-day
mortality.
Secondary outcome measures are: (1) all-cause mortal-
ity within the total observation time, measured 30 days
after the last included patient; (2) admission to an inten-
sive care unit, and duration thereof, within 30 days of
randomisation; and (3) duration of hospitalisation post-
operatively (days).
Data collection and trial conduct
Data are collected on printed case report forms, on
which a unique barcode number is printed to eliminate
the possibility of duplication of the case report forms.
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the Verity TeleformW system (Verity, Sunnyvale, CA,
USA) managed by Copenhagen Trial unit. Mortality data
is extracted from The CRS. The Steering Committee will
not have access to the dataset until the trial has been
completed. The InCare trial is conducted in compliance
with the Helsinki Declaration, and is approved by the
Copenhagen Capital Region Ethical board (H-3-2010-
010) and the Danish Data Protection Agency (HEH.afd.
I.750.16-18). The trial is registered at clinicaltrials.gov
(NCT01209663), and conducted and monitored in ac-
cordance with the ICH-GCP guidelines. Case report
forms are checked for validity and internal consistency
through trial site visits by Good Clinical Practice (GCP)
monitors, who checks source data in approximately 10%
of the case report forms selected at random. The trial is
designed in compliance with the Consort Statement, and
the two extensions: ‘Improving reporting of pragmatic
trials’ and ‘Extending the consort statement to rando-
mised trials of nonpharmacologic trials’ [41-43].
Interim analyses
We have established an independent Data Monitoring
Committee (DMC) to evaluate safety and efficacy on
scheduled interim analyses of 30-day mortality data. The
monitoring plan is based on the modified Haybittle-Peto
boundaries for stopping trials after interim analyses in
the second half of the inclusion period [44,45]. The mor-
tality data are presented to the DMC under a blinded
code for allocation group. The first interim analysis will
be conducted when 30-day mortality data of 200 trial
participants have been obtained, and/or 75 deaths have
been documented during the trial. If the first interim ana-
lysis of 30-day mortality data is significant (P <0.001) for
benefit or harm from the intervention, a second interim
analysis will be made when 30-day mortality data of 300
trial participants have been obtained and/or an additional
25 deaths have been documented. If the second interim
analysis is also statistically significant (P <0.001) for bene-
fit or harm from the intervention the DMC can advise the
steering committee to stop the trial.
Statistical analysis
The outcome measures will be analysed for all rando-
mised patients in a modified intention-to-treat analysis
leading to the primary results of the trial [46]. Patients
with the following major protocol violations will not be
included in a per-protocol analysis: not fulfilling an in-
clusion criterion; fulfilling an exclusion criterion; IC for
<48 h because of early discharge to the ward. The pri-
mary outcome measure, 30-day mortality, will be analysed
with an unadjusted univariate logistic regression, and a
multivariate logistic regression analysis will be made
adjusting for stratification variables: trial-site, APACHE IIscore (10 to 14 or ≥15), and perforated viscera (yes versus
no); and design variables: age, ASA score (1 to 2 or ≥3),
cancer, and nature of surgery (+/− re-operation). The
secondary outcome measure, survival within the total ob-
servation time, will be analysed with an unadjusted Cox
regression analysis, and a Cox regression analysis adjusted
for the above-mentioned stratification variables and design
variables [47]. Survival within the total observation time
will be illustrated with Kaplan-Meier estimates. Fisher’s
exact or chi-squared tests will be used, depending on
values, to analyse the differences of frequencies of regis-
tered complications in the two groups. Mortality data will
be retrieved on patients registered as ‘not included in the
trial due to lack of IC bed’. The data on these patients will
be compared with that from the WC group, then included
with the WC group data and compared with the IC group.
Data on a semi-quantitative scale will be analysed using
the Mann–Whitney test. Double sided P values <0.05 will
be considered statistically significant.
Sample size
Emergency major abdominal surgical patients with an
APACHE II score ≥10/11 have a 28% to 45% mortality
rate [27-31]. We assume that patients with an APACHE
II score of ≥10 have a 30-day mortality of 38%. We aim
to confirm or reject an intervention effect of 13% abso-
lute risk reduction in mortality (a relative risk reduction
of 34%), in accordance with the difference between
group mortality detected in our recent observational
study of optimised perioperative care in perforated pep-
tic ulcer patients [48]. The sample size with a type 1 error
risk of 5%, and a type 2 error risk of 20% (80% power),
was estimated to 200 patients in each group [49].
Ethical considerations
Randomised trials in presumed optimised health-care
protocols are associated with unique ethical problems,
especially when mortality is the outcome measure.
Patients often intuitively find the IC appealing when the
interventions are outlined for them, but IC is only avail-
able by chance if they consent to participate in the trial.
In this design it is of utmost importance to consider that
the effect of postoperative intermediate care, with a
package of possible interventions, remains to be proven.
Furthermore, participants are exclusively enrolled post-
operatively when they fulfill the current discharge cri-
teria to be transferred to the surgical ward, which
ensures that the control group is given the best current
available standard treatment.
In the InCare trial, all diagnostic tests and interven-
tions in the control and intervention group are initiated
by the attending doctors, thereby reflecting their medical
judgment, and not alone the trial protocol. We are thus
only evaluating the effect of the extra monitoring, extra
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with differences in routine, resources, and capability.
Trial management
The InCare trial is investigator initiated, controlled by a
steering committee including anaesthetists, intensivists
and surgeons, all with solid research experience. The
committee is responsible for the planning, design and
conduct of the trial. At each trial site two or three site
investigators with at least one surgeon and one intensi-
vist/anaesthetist manage the local implementation. This
includes teaching and supervising of staff, daily manage-
ment, and data collection with support from the principal
coordinating investigator. Protocol observance is stimu-
lated by repeated staff educational sessions on patient en-
rolment, and execution of the trial interventions by the
site investigators and the coordinating investigator. Add-
itionally, intervention period data are checked to monitor
adherence to protocol, thereby giving feedback to staff. A
monthly newsletter with trial updates is sent to the
involved parties, and published on the trial website.
Discussion
Trial rationale
Participants
Our recent findings in emergency surgical patients with
perforated ulcer [48] suggested that we should investigate
the effects of IC in emergency major abdominal surgical
patients with an APACHE II score ≥10. The APACHE II
index is well-known to anaesthetists responsible for pa-
tient enrolment, and it reflects the presence of periopera-
tive sepsis, cardiovascular and respiratory failure.
Interventions
The level of care in the IC group is based on national
and international definitions, descriptions, surveys and
recommendations which may increase the external
validity [15,50-53].
We chose an IC admission duration of 48 h influenced
by the findings of Garmil et al. [54] that 80% of patients
dying or disabled in hospital began to deteriorate within
24 h postoperatively, and of Jhanji et al. [13] that surgi-
cal ward admission was approximately 48 h prior to the
necessary postoperative intensive care unit admission.
Furthermore, this duration of the IC intervention was
conceived realistic in that it could be accepted by the
participating trial sites.
Daily protocol-based rounds are made in the IC group
to ensure uniform evaluation at the participating trial
sites, thus improving internal validity. The rounds made
by surgeons and intensivists, are aimed at optimising pain
relief, cardiopulmonary function, fluid balance, nutrition,
mobilisation and early detection of complications.The WC group receives ward care according to local
standards. We choose not to reinforce a treatment and
monitoring protocol in the WC group, as we wish to
compare IC with standard care at the participating trial
sites. With trial site stratified randomisation, we aim to
adjust for possible differences in standard care at the
wards. Additionally, we register intervention period data
on level of treatment and monitoring as in the IC group,
which enable us to report the actual level of treatment
and monitoring in the wards.
In the WC group, intervention period data collection
is made on day 14, because data collection on day 2
would equate with an extra clinical evaluation and the
possible initiation of treatment, which could differ from
current standard care.
Previous research
The effect of postoperative IC is unresolved in high-
evidence studies. Previous studies of IC have been non-
randomised, observational or descriptive, often with
contradictory results [17-23]. Davies et al. and Bellomo
et al. [18,19] found no reduction in postoperative in-
hospital mortality or morbidity following introduction of
an IC unit at their facilities. Both studies reported a
change in surgical intake tending more to emergency
surgery after introduction of the IC unit. This may ex-
plain the lack of effect in their unadjusted analyses.
Turner et al. [20] found an excess crude mortality rate
in patients not admitted to IC units despite requests
from the attending surgeon or anaesthetist. In a similar
design McIlroy et al. [21] concluded that IC may lead to
longer hospital stay, but no effect on 30-day mortality or
all-cause morbidity could be shown. Jones et al. [22]
compared two hospitals (one with, and one without, an
IC unit). This study suggested that postoperative IC
might reduce cardiopulmonary complications after
major abdominal surgery, when risk adjusting with
Physiologic and Operative Severity Score for the enu-
meration of mortality and morbidity (POSSUM score).
No effect on mortality or length of hospital stay could
be shown. Swart et al. [23] compared postoperative in-
tensive care with surgical ward care in colorectal surgical
patients with a preoperative anaerobic threshold <11 mL
oxygen/ kg/min. They found that there was significant
decrease in cardiac adverse events in the intensive care
patients, but no effect on in-hospital mortality, or length
of hospital stay could be shown.
Common in the previous research is a high risk of bias
as confounding by indication and selection bias, and
thereby unbalanced number of risk patients in the com-
pared groups is imminent. Furthermore, the cited
studies are characterised by limited power to show effect
on mortality, because they predominantly investigate
patients undergoing scheduled surgical procedures
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Strengths
The InCare trial is the first randomised clinical trial to
evaluate the effect of postoperative intermediate care.
The design will provide evidence with low risk of bias
compared with previous studies.
We have thoroughly described the complex intervention
in the IC group and the compliance with protocol is rigor-
ously registered to improve internal validity, and transpar-
ent reporting of the trial. IC is evaluated in high-risk
emergency abdominal surgical patients with high mortal-
ity. This enables us to report all-cause mortality, in a rele-
vant patient population, which we believe is the most
relevant primary outcome measure when evaluating IC.
We have chosen not to report postoperative complications
as an outcome measure. Our hypothesis is that the IC will
lead to avoidance or earlier recognition of postoperative
complications. Reporting complications when evaluating
IC compared with WC can be misleading in that IC may
reduce complications because of early postoperative opti-
misation, or show an increase in registered complications
because of more intensive controls, for example, X-rays/
atelectasis, which might not be detected on the ward and
spontaneously resolve. Given that the IC both can lead to
a decrease (avoidance of complications) or an increase
(recognition of complications) in the registered postopera-
tive complication rate, appropriate conclusions on these
outcomes will be difficult in the case of no mortality effect
because of type II error. Additionally, if complications
were to be reported as an outcome measure, a detailed
prospective bedside registration during the first 14 to
30 days after surgery would be necessary. These investiga-
tor follow-up visits would be equivalent to extra clinical
evaluations of the patients, which might well entail change
in the current standard care in the IC and WC groups.
This could potentially jeopardise the external validity of
the primary outcome measure and conceal a beneficial
effect of IC on mortality.
Limitations
In this pragmatic clinical trial some important limitations
must be noted. Unfortunately, it is not possible to blind
the involved healthcare personnel, or the participants, in
this trial, and outcome assessment is only partially blinded.
Given that the data on mortality are retrieved from The
Danish Civil Registration System the risk of detection bias
is minimal compared to, for example, an assessment of
postoperative complications as an outcome. The lack of
blinding, and the fact that the same surgeons at the same
hospital treat both the IC and WC group may insinuate a
learning bias possibly concealing a beneficial effect of the
IC. In the InCare trial the WC group receives localstandard care, which is not rigorously defined by the proto-
col. This is a limitation. Our efforts to register intervention
period data will provide important information on the
actual monitoring and treatment given to the WC group,
and will also expose any learning bias in the WC group.
The intervention is complex, and the involvement of
several trial sites entails the risk that not all elements of
intervention are uniformly applied. Nevertheless, these
deviations may reflect clinical practice, and the transpar-
ent reporting will give ground for a fair interpretation of
the trial result. Finally, as this trial is the first of its kind,
the sample size calculation is based on estimates, which
entails a risk of type II error, thus not detecting a smaller
intervention effects than the anticipated relative risk re-
duction of 34% used in our sample size estimation.
Conclusion
The InCare trial is the first randomised clinical trial that
aims to contribute to answer the important research ques-
tion: should high-risk surgical patients receive postopera-
tive intermediate care. The results may potentially
influence the survival of many high-risk surgical patients.
As a pioneer trial in the area, it will provide important
data on the feasibility of a future large randomised clinical
trial, which may definitively settle the question.
Trial status
All Danish public-healthcare centres that receive emer-
gency major abdominal surgical patients were asked to
participate in the trial (n = 23). The reasons for declining
to participate were: limited intensive/intermediate care
facilities (n = 8); high-risk surgical patients treated >24 h
postoperatively in a post-anaesthesia care unit or an
intermediate/intensive care unit (n = 3); conflicting re-
search projects (n = 2); lack of resources to conduct
more than one multicentre clinical trial (n = 1), and no
answer after multiple contacts (n = 2).
Seven centres thus currently participate in the trial
and have started enrolment: Herlev Hospital, 4 October
2010 (n = 80); Koege Hospital, 11 October 2010 (n = 35);
Hilleroed Hospital, 15 November 2010 (n = 36); Herning
Hospital, 2 May 2011 (n = 19); Aabenraa Hospital, 1 July
2011 (n = 2); Bispebjerg Hospital, 1 December 2011
(n = 17); and Vejle Hospital, 1 February 2012 (n = 10).
To date (1 June 2012) 199 patients have been enrolled.
Additional files
Additional file 1: Search string.
Additional file 2: National discharge recommendations.
Additional file 3: Surgeon - protocol-based round.
Additional file 4: Intensivist - protocol-based round.
Additional file 5: Anaesthetist - discharge note.
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